Imvax has concluded the enrolment of participants in the Phase IIb clinical trial of IGV-001 to treat patients with newly diagnosed glioblastoma (GB).

An autologous biologic-device combination product, IGV-001, utilises the patient’s tumour cells to trigger a comprehensive and long-lasting immune response against cancer.

The multi-centre, randomised, double-blind, placebo-controlled study will evaluate the safety and efficacy of IGV-001 in around 100 participants.

Participants were assigned to a 2:1 ratio across 20 sites in the US.

Following surgical resection, patients in the trial’s IGV-001 arm received biodiffusion chambers implanted with a mix of personalised whole tumour-derived cells and an antisense oligonucleotide (IMV-001).

Those in the placebo arm received chambers with an inactive solution.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Progression-free survival (PFS) is the trial’s primary endpoint while overall survival (OS) and safety will be assessed as key secondary endpoints.

Top-line data from the trial is anticipated to be released by mid-2025.

In a separate development, the US Food and Drug Administration (FDA) granted fast-track designation to IGV-001 to treat ndGBM.

The decision is influenced by promising Phase Ib data that suggested significant therapeutic potential for this condition.

Imvax also secured approximately $35m in a funding round, and half of the investment came from new investors.

To support the completion of the Phase IIb trial of IGV-001, the company secured $57m over the past 15 months.

Imvax CEO John Furey said: We are also delighted that the FDA has granted fast track designation to IGV-001.

“The last significant advancement in the standard of care for GBM – about an eight-week improvement in PFS – was nearly 20 years ago, highlighting the need for continued innovation and treatment options. We believe IGV-001 may offer meaningful clinical benefit for patients diagnosed with this deadly disease.”